Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T81744 | mTOR inhibitor-14 | mTOR | PI3K/Akt/mTOR signaling |
mTORinhibitor-14(compound 14c)是一种mTOR高效抑制剂,对CYP2C8的抑制作用较弱,并能有效抑制肿瘤生长。 | |||
T81470 |
PI3K/mTOR Inhibitor-14
|
PI3K | PI3K/Akt/mTOR signaling |
PI3K/mTOR Inhibitor-14(化合物 Y-2)是一种针对PI3K和mTOR的双重抑制剂,其IC50值分别为171.4 nM 和10.1 nM ,具备抗肿瘤活性。 | |||
T3656 |
PKI-402
|
PI3K; mTOR | PI3K/Akt/mTOR signaling |
PKI-402 是一种有效的 PI3K 和 mTOR 抑制剂,对 PI3Kα, mTOR, PI3Kβ, PI3Kδ 和 PI3Kγ 抑制的IC50 分别为 2, 3, 7, 14 和 16 nM。 | |||
T2415 |
PP121
|
Apoptosis; VEGFR; Bcr-Abl; PDGFR; Src; mTOR; Hck | Angiogenesis; Apoptosis; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
PP121是一种多靶点激酶抑制剂,抑制 PDGFR、Hck、mTOR、VEGFR2、Src、Abl、DNK-PK 的 IC50值分别为2、8、10、12、14、18、60 nM。 | |||
T6276 |
KU-57788
NU7441 |
DNA-PK; CRISPR/Cas9 | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
KU-57788 (NU7441) 是一种 NHEJ 通路抑制剂,抑制 PI3K 和 mTOR,IC50分别为 5.0 和 1.7 μM。 它是高效的选择性DNA-PK 抑制剂,IC50为 14 nM。 | |||
T1916 |
Apitolisib
RG 7422,GNE 390,GDC-0980 |
Apoptosis; PI3K; mTOR | Apoptosis; PI3K/Akt/mTOR signaling |
Apitolisib (RG 7422) 是一种口服有效的 PI3K 和 mTOR(TORC1/2) 激酶抑制剂,抑制 PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ的活性,IC50值为 5 nM/27 nM/7 nM/14 nM,抑制 mTOR,Ki 为 17 nM。它用于乳腺癌、前列腺癌、肾细胞癌和子宫内膜癌等实体癌的试验研究 。 | |||
T36084 |
PKI-179
|
||
PKI-179 is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo[1][2]. PKI-179 inhibits the cell proliferation, with IC50s of 22 nM and 29 nM for MDA361 and PC3 cells, respectively[1].PKI-179 shows inhibitory activity against a panel of 361 other ... | |||
T36085 | PKI-179 hydrochloride | ||
PKI-179 is an orally bioavailable dual inhibitor of PI3K and mammalian target of rapamycin (mTOR). In an in vitro enzymatic assay, it potently inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, respectively), two common PI3Kα mutants, E545K and H1047R (IC50s = 14 and 11 nM, respectively), and mTOR (IC50 = 0.42 nM). PKI-179 is selective for PI3K and mTOR over a panel of 361 other kinases at IC50 values up to 50 μM, hERG (IC50 > 30 μM), and cytochrome P450 (CYP) isoforms (IC5... |